Analysts: Gilead Sciences Inc (GILD.O)
GILD.O on Nasdaq
57.08USD
12:34pm EDT
57.08USD
12:34pm EDT
Price Change (% chg)
$0.61 (+1.08%)
$0.61 (+1.08%)
Prev Close
$56.47
$56.47
Open
$57.00
$57.00
Day's High
$58.06
$58.06
Day's Low
$56.65
$56.65
Volume
6,805,647
6,805,647
Avg. Vol
11,796,014
11,796,014
52-wk High
$58.06
$58.06
52-wk Low
$24.12
$24.12
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | 0.49 | December | 22 May 2013 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 13 | 13 | 13 | 14 |
| (2) OUTPERFORM | 11 | 12 | 11 | 10 |
| (3) HOLD | 5 | 5 | 5 | 5 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.72 | 1.73 | 1.72 | 1.69 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-13 | 23 | 2,646.84 | 2,810.00 | 2,533.80 | 2,443.15 |
| Quarter Ending Sep-13 | 23 | 2,670.91 | 2,775.90 | 2,570.90 | 2,442.18 |
| Year Ending Dec-13 | 28 | 10,610.00 | 11,018.30 | 10,276.30 | 9,933.94 |
| Year Ending Dec-14 | 27 | 12,921.30 | 13,970.20 | 11,005.80 | 11,244.40 |
| Earnings (per share) | |||||
| Quarter Ending Jun-13 | 25 | 0.49 | 0.56 | 0.46 | 0.55 |
| Quarter Ending Sep-13 | 25 | 0.48 | 0.56 | 0.44 | 0.58 |
| Year Ending Dec-13 | 31 | 1.97 | 2.23 | 1.84 | 2.19 |
| Year Ending Dec-14 | 30 | 2.90 | 3.46 | 2.09 | 2.76 |
| LT Growth Rate (%) | 9 | 26.66 | 45.30 | 17.00 | 15.80 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-13 | 2,583.61 | 2,531.64 | 51.97 | 2.01 |
| Quarter Ending Dec-12 | 2,433.82 | 2,588.28 | 154.47 | 6.35 |
| Quarter Ending Sep-12 | 2,339.25 | 2,426.60 | 87.35 | 3.73 |
| Quarter Ending Jun-12 | 2,293.48 | 2,405.19 | 111.70 | 4.87 |
| Quarter Ending Mar-12 | 2,200.57 | 2,282.45 | 81.88 | 3.72 |
| Earnings (per share) | ||||
| Quarter Ending Mar-13 | 0.50 | 0.48 | 0.02 | 3.03 |
| Quarter Ending Dec-12 | 0.48 | 0.50 | 0.02 | 5.13 |
| Quarter Ending Sep-12 | 0.47 | 0.50 | 0.03 | 6.56 |
| Quarter Ending Jun-12 | 0.47 | 0.50 | 0.02 | 4.30 |
| Quarter Ending Mar-12 | 0.47 | 0.46 | 0.01 | 2.65 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-13 | 2,646.84 | 2,646.91 | 2,661.27 | 2,645.87 | 2,443.15 |
| Quarter Ending Sep-13 | 2,670.91 | 2,670.98 | 2,687.57 | 2,675.89 | 2,442.18 |
| Year Ending Dec-13 | 10,610.00 | 10,610.50 | 10,674.90 | 10,644.30 | 9,933.94 |
| Year Ending Dec-14 | 12,921.30 | 12,892.00 | 12,801.60 | 12,511.10 | 11,244.40 |
| Earnings (per share) | |||||
| Quarter Ending Jun-13 | 0.49 | 0.49 | 0.50 | 0.49 | 0.55 |
| Quarter Ending Sep-13 | 0.48 | 0.48 | 0.49 | 0.49 | 0.58 |
| Quarter Ending Dec-13 | 1.97 | 1.98 | 2.02 | 2.02 | 2.19 |
| Quarter Ending Dec-14 | 2.90 | 2.90 | 2.87 | 2.79 | 2.76 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-13 | 0 | 2 | 10 | 11 |
| Quarter Ending Sep-13 | 0 | 2 | 11 | 10 |
| Year Ending Dec-13 | 0 | 2 | 8 | 16 |
| Year Ending Dec-14 | 2 | 0 | 14 | 8 |
| Earnings | ||||
| Quarter Ending Jun-13 | 0 | 0 | 7 | 12 |
| Quarter Ending Sep-13 | 0 | 0 | 3 | 13 |
| Year Ending Dec-13 | 0 | 1 | 6 | 18 |
| Year Ending Dec-14 | 2 | 0 | 8 | 14 |
Earnings vs. 
Estimates- Experimental Gilead drug effective in early-stage leukemia trial
- Experimental Gilead drug effective in early-stage leukemia trial
- Gilead profit rises, but sales of older HIV drugs dip
- UPDATE 2-Gilead profit rises, but sales of older HIV drugs dip
- CORRECTED-Gilead profit rises 63 pct, sales of older HIV drugs dip
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Jefferson Research
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
